MD Anderson and Daiichi Sankyo said their collaboration will focus on carrying out “numerous” clinical trials assessing combination regimens that use several investigational compounds from Daiichi Sankyo’s pipeline and multiple other treatments. The collaboration plans to launch multiple Phase I and Phas...
Also, presence of FLT3 -ITD mutation may be a negative prognostic marker, not only at diagnosis but also at first relapse. Several small-molecule FLT3 inhibitors are currently in clinical trials and may improve responses for patients with FLT3 -mutated AML....
“At this time, there is really no clear way to direct or eradicate MRD in patients with AML,” said Daver, who is director of the Leukemia Research Alliance Program, and an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. “Although ...
Rigel president and CEO Raul Rodriguez said: “We are excited to enter into this strategic alliance with the exceptional team at MD Anderson to evaluate REZLIDHIA as a potential therapy for a broad range of IDH1-mutant cancers. “We believe REZLIDHIA has the potential to become a standard o...
We now have combinations in clinical trials with venetoclax and HMAs. HMAs upregulate CD47, and venetoclax lowers the apoptotic threshold. [These studies] will be a step forward, but we still have a way to go with p53 mutations. Splice site mutations are being targeted. Omar Abdel-Wahab, MD...
[enasidenib’s] established role as a treatment option for patients with relapsed/refractory AML with an IDH2 mutation and are grateful to all those who participated in the study,” Noah Berkowitz, MD, PhD, senior vice president of Global Clinical Development, Hematology at BMS, ...
Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Partow Kebriaei Division of Hematology and Oncology, and Stem Cell Transplant Program, Case Western Reserve University, Cleveland, OH, USA ...
providing important information about dysregulated signaling involved in leukemic transformation and leading to new therapeutic targets,” said Elias Jabbour, MD, an associate professor at The University of Texas MD Anderson Cancer Center in Houston, during a recent OncLive® Peer Exchange® program....
Nitin Jain, MD, associate professor in the department of leukemia, division of cancer medicine, at The University of Texas MD Anderson Cancer Center, discusses clinical trials investigating allogeneic chimeric antigen receptor (CAR) T-cell therapy for B-cell acute lymphoblastic leukemia (B-ALL)...
Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses agents being investigated in acute myeloid leukemia (AML). Recent Videos Ga 68 PSMA-11 in BgRT: Targeting Bony Metastases in Prostate Cancer ...